Division of Neonatology, Department of Pediatrics, University of Rochester Medical Center, Rochester, NY, USA.
J Perinat Med. 2011 Jan;39(1):55-8. doi: 10.1515/jpm.2010.113. Epub 2010 Oct 18.
To evaluate the effect of ibuprofen on bilirubin-albumin binding affinity and unbound bilirubin in premature infants.
A prospective study with subjects serving as their own controls was performed on <30 weeks' gestational age infants with unconjugated hyperbilirubinemia and who received ibuprofen for patent ductus arteriosus. Infants with congenital malformation, TORCH infections, and conjugated hyperbilirubinemia were excluded. Total serum bilirubin (TSB) and unbound bilirubin (modified peroxidase test) were measured prior to (baseline) and after (follow-up) initiation of ibuprofen. The bilirubin/albumin equilibrium association binding constant was calculated using albumin, TSB, and unbound bilirubin.
Ten infants were studied. The mean TSB between baseline (5.9±1.7 mg/dL) was higher than that at follow-up [4.9±1.7 mg/dL]. Mean unbound bilirubin at baseline (0.75±0.65 μg/dL) was similar to that at follow-up (0.63±0.46 μg/dL). No difference existed between mean baseline binding constant (49±50 L/μmol) and that at follow-up (44±36 L/μmol). The ratio of unbound bilirubin with and without ibuprofen, index of displacing effect, was 0.88 (95% CI 0.63-1.14).
Ibuprofen may not be associated with bilirubin displacing effect in relatively stable premature infants with mild to moderate unconjugated hyperbilirubinemia.
评估布洛芬对胆红素-白蛋白结合亲和力和未结合胆红素的影响在早产儿。
对胎龄<30 周、有未结合高胆红素血症且接受布洛芬治疗动脉导管未闭的早产儿进行前瞻性研究,以自身为对照。排除有先天畸形、TORCH 感染和结合性高胆红素血症的婴儿。在开始使用布洛芬之前(基线)和之后(随访)测量总血清胆红素(TSB)和未结合胆红素(改良过氧化物酶试验)。使用白蛋白、TSB 和未结合胆红素计算胆红素/白蛋白平衡结合常数。
10 名婴儿被纳入研究。基线时的平均 TSB(5.9±1.7mg/dL)高于随访时的 TSB(4.9±1.7mg/dL)。基线时的平均未结合胆红素(0.75±0.65μg/dL)与随访时的未结合胆红素相似(0.63±0.46μg/dL)。基线时的平均结合常数(49±50L/μmol)与随访时的结合常数(44±36L/μmol)无差异。有无布洛芬时未结合胆红素的比值,即置换效应指数,为 0.88(95%可信区间为 0.63-1.14)。
在相对稳定的、有轻度至中度未结合高胆红素血症的早产儿中,布洛芬可能与胆红素置换效应无关。